We are live on ! Find out more
PDSB icon

PDS Biotechnology
PDSB

57 hedge funds and large institutions have $16.6M invested in PDS Biotechnology in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more call options, than puts

Call options by funds: $1.35M | Put options by funds: $278K

3% more capital invested

Capital invested by funds: $16.1M → $16.6M (+$448K)

3.22% less ownership

Funds ownership: 15% → 11.79% (-3.2%)

26% less funds holding

Funds holding: 77 → 57 (-20)

57% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 21

75% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 24

Holders
57
Holders Change
-20
Holders Change %
-25.97%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
21
Closed
24
Calls
$1.35M
Puts
$278K
Net Calls
+$1.07M
Net Calls Change
+$500K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$376K
2
Citadel Advisors
Citadel Advisors
Florida
+$221K
3
XT
XTX Topco
Cayman Islands
+$159K
4
SPA
Sherbrooke Park Advisers
New York
+$134K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$930K
2
Northern Trust
Northern Trust
Illinois
-$492K
3
Millennium Management
Millennium Management
New York
-$491K
4
SI
Sofinnova Investments
California
-$418K
5
Jane Street
Jane Street
New York
-$334K
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
26
Cubist Systematic Strategies
Connecticut
$69.5K -$105K -31,580 -63%
Two Sigma Investments
27
Two Sigma Investments
New York
$67.2K – – –
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$59.9K +$22.4K +6,726 +75%
WG
29
Wealth Group
North Carolina
$59K – – –
MG
30
Marex Group
$53.5K – – –
Invesco
31
Invesco
Georgia
$52.8K +$2.14K +641 +5%
Charles Schwab
32
Charles Schwab
California
$50.7K – – –
LCM
33
Lazari Capital Management
California
$49.7K – – –
Mercer Global Advisors
34
Mercer Global Advisors
Colorado
$45.6K – – –
RJA
35
Raymond James & Associates
Florida
$44.8K -$7.08K -2,121 -15%
LPL Financial
36
LPL Financial
California
$39.8K – – –
FDCDDQ
37
Federation des caisses Desjardins du Quebec
Quebec, Canada
$34.4K – – –
KSWA
38
Kathleen S. Wright Associates
Pennsylvania
$26.7K – – –
Simplex Trading
39
Simplex Trading
Illinois
$25K -$90.6K -27,144 -80%
CFM
40
Catalyst Funds Management
Australia
$21.4K – – –
Osaic Holdings
41
Osaic Holdings
Arizona
$20.1K – – –
Wells Fargo
42
Wells Fargo
California
$18.1K +$4.1K +1,229 +35%
BTI
43
Blue Trust Inc
Georgia
$13.2K +$15K +4,500 New
TRCT
44
Tower Research Capital (TRC)
New York
$10.6K -$40.6K -12,174 -81%
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$10K -$30.1K -9,016 -78%
Fidelity Investments
46
Fidelity Investments
Massachusetts
$8.44K -$744 -223 -9%
CFD
47
Creative Financial Designs
Indiana
$7.83K – – –
WWP
48
WR Wealth Planners
Missouri
$7.64K – – –
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$4.88K -$28.7K -8,603 -87%
TC
50
Truvestments Capital
Florida
$4.24K +$3.71K +1,111 New
1
2
3 4

PDSB Hedge Fund Activity: Q3 2024 in Review

57 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2024, worth a combined $16.6M — up 2.8% from $16.1M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of PDSB and 6 opened new positions — a net loss of 18 holders — while 21 trimmed existing stakes and 9 added.

The largest buyer was Vanguard Group, adding an estimated $376K. The largest seller was Goldman Sachs, exiting entirely with an estimated $930K sold.

  • 57 institutional investors held PDS Biotechnology (PDSB) as of Q3 2024, down from 77 in Q2 2024.
  • Funds reported $16.6M of PDS Biotechnology stock for Q3 2024, up 2.8% quarter-over-quarter.
  • 6 funds opened new PDS Biotechnology positions in Q3 2024 and 24 closed out, a net change of -18 holders.
  • The largest PDS Biotechnology buyer in Q3 2024 was Vanguard Group, an estimated $376K added.
  • The largest PDS Biotechnology seller in Q3 2024 was Goldman Sachs, an estimated $930K sold.

Based on aggregated 13F filings for Q3 2024.